tetano
Editor, Senior Moderator
Clin Infect Dis
. 2020 Aug 17;ciaa1196.
doi: 10.1093/cid/ciaa1196. Online ahead of print.
Highly sensitive quantification of plasma SARS-CoV-2 RNA shelds light on its potential clinical value
David Veyer[SUP] 1 2 [/SUP], Solen Kern?is[SUP] 3 4 5 [/SUP], Geoffroy Poulet[SUP] 6 [/SUP], Maxime Wack[SUP] 7 8 [/SUP], Nicolas Robillard[SUP] 1 [/SUP], Val?rie Taly[SUP] 5 [/SUP], Anne-Sophie L'Honneur[SUP] 9 [/SUP], Flore Rozenberg[SUP] 9 [/SUP], Pierre Laurent-Puig[SUP] 5 10 [/SUP], Laurent B?lec[SUP] 1 11 [/SUP], J?r?me Hadjadj[SUP] 12 13 [/SUP], Benjamin Terrier[SUP] 13 11 [/SUP], H?l?ne P?r?[SUP] 1 14 [/SUP]
Affiliations
Abstract
Background: Coronavirus disease 2019 (COVID-19) is a global public health problem that has already caused more than 662,000 deaths worldwide. Although the clinical manifestations of COVID-19 are dominated by respiratory symptoms, some patients present other severe damage such as cardiovascular, renal and liver injury or/and multiple organ failure, suggesting a spread of the SARS-CoV-2 in blood. Recent ultrasensitive polymerase chain reaction (PCR) technology now allows absolute quantification of nucleic acids in plasma. We herein intended to use the droplet-based digital PCR technology to obtain sensitive detection and precise quantification of plasma SARS-CoV-2 viral load (SARS-CoV-2 RNAaemia) in hospitalized COVID-19 patients.
Methods: Fifty-eight consecutive COVID-19 patients with pneumonia 8 to 12 days after onset of symptoms and 12 healthy controls were analyzed. Disease severity was categorized as mild-to-moderate in 17 patients, severe in 16 patients and critical in 26 patients. Plasma SARS-CoV-2 RNAaemia was quantified by droplet digital Crystal Digital PCR™ next-generation technology (Stilla Technologies, Villejuif, France).
Results: Overall, SARS-CoV-2 RNAaemia was detected in 43 (74.1%) patients. Prevalence of positive SARS-CoV-2 RNAaemia correlated with disease severity, ranging from 53% in mild-to-moderate patients to 88% in critically ill patients (p=0.036). Levels of SARS-CoV-2 RNAaemia were associated with severity (p=0.035). Among nine patients who experienced clinical deterioration during follow-up, eight had positive SARS-CoV-2 RNAaemia at baseline while only one critical patient with undetectable SARS-CoV-2 RNAaemia at the time of analysis died at day 27.
Conclusion: SARS-CoV-2 RNAaemia measured by droplet-based digital PCR constitutes a promising prognosis biomarker in COVID-19 patients.
. 2020 Aug 17;ciaa1196.
doi: 10.1093/cid/ciaa1196. Online ahead of print.
Highly sensitive quantification of plasma SARS-CoV-2 RNA shelds light on its potential clinical value
David Veyer[SUP] 1 2 [/SUP], Solen Kern?is[SUP] 3 4 5 [/SUP], Geoffroy Poulet[SUP] 6 [/SUP], Maxime Wack[SUP] 7 8 [/SUP], Nicolas Robillard[SUP] 1 [/SUP], Val?rie Taly[SUP] 5 [/SUP], Anne-Sophie L'Honneur[SUP] 9 [/SUP], Flore Rozenberg[SUP] 9 [/SUP], Pierre Laurent-Puig[SUP] 5 10 [/SUP], Laurent B?lec[SUP] 1 11 [/SUP], J?r?me Hadjadj[SUP] 12 13 [/SUP], Benjamin Terrier[SUP] 13 11 [/SUP], H?l?ne P?r?[SUP] 1 14 [/SUP]
Affiliations
- PMID: 32803231
- DOI: 10.1093/cid/ciaa1196
Abstract
Background: Coronavirus disease 2019 (COVID-19) is a global public health problem that has already caused more than 662,000 deaths worldwide. Although the clinical manifestations of COVID-19 are dominated by respiratory symptoms, some patients present other severe damage such as cardiovascular, renal and liver injury or/and multiple organ failure, suggesting a spread of the SARS-CoV-2 in blood. Recent ultrasensitive polymerase chain reaction (PCR) technology now allows absolute quantification of nucleic acids in plasma. We herein intended to use the droplet-based digital PCR technology to obtain sensitive detection and precise quantification of plasma SARS-CoV-2 viral load (SARS-CoV-2 RNAaemia) in hospitalized COVID-19 patients.
Methods: Fifty-eight consecutive COVID-19 patients with pneumonia 8 to 12 days after onset of symptoms and 12 healthy controls were analyzed. Disease severity was categorized as mild-to-moderate in 17 patients, severe in 16 patients and critical in 26 patients. Plasma SARS-CoV-2 RNAaemia was quantified by droplet digital Crystal Digital PCR™ next-generation technology (Stilla Technologies, Villejuif, France).
Results: Overall, SARS-CoV-2 RNAaemia was detected in 43 (74.1%) patients. Prevalence of positive SARS-CoV-2 RNAaemia correlated with disease severity, ranging from 53% in mild-to-moderate patients to 88% in critically ill patients (p=0.036). Levels of SARS-CoV-2 RNAaemia were associated with severity (p=0.035). Among nine patients who experienced clinical deterioration during follow-up, eight had positive SARS-CoV-2 RNAaemia at baseline while only one critical patient with undetectable SARS-CoV-2 RNAaemia at the time of analysis died at day 27.
Conclusion: SARS-CoV-2 RNAaemia measured by droplet-based digital PCR constitutes a promising prognosis biomarker in COVID-19 patients.